Research Site

Göttingen DE-37099

9 studies enrolling now · 36 studies all time

What they study most

Active Systemic Lupus Erythematosus, Acute Coronary Syndrome, Acute Intracranial Hemorrhage, Advanced Breast Cancer, Anemia, Anxiety Disorders, B-cell Malignancies, Biliary Tract Cancer, Breast Cancer, Carcinoma, Non-Small-Cell Lung, Cardiovascular Disease, Chronic Kidney Disease and Hypertension

Studies at this site

• A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. — Recruiting now
• Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer — Recruiting now
• A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure — Recruiting now
• A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation — Recruiting now
• A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients — Recruiting now
• Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma — Recruiting now
• Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer — Recruiting now
• A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event — Recruiting now
• Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function — Recruiting now
• A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer — Recruiting now
• Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer — Recruiting now
• Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation — Running, not enrolling
• Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC — Running, not enrolling
• Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC — Running, not enrolling
• AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 — Running, not enrolling
• A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration — Stopped early
• Tracking Treatment Pathways in Adult Patients With Hyperkalemia. — Completed
• Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis — Stopped early
• Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer — Completed
• Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor — Completed
• Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma — Completed
• Study of Verinurad in Heart Failure With Preserved Ejection Fraction — Completed
• Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus — Completed
• RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial — Completed
• Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction — Completed
• Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis — Completed
• Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer — Completed
• Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy — Completed
• A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma — Completed
• Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma — Completed
• ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures — Completed
• A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer — Stopped early
• A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer — Completed
• A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome — Completed
• Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease — Completed
• Safety and Efficacy Maintenance Study of Quetiapine SR to Treat GAD Patients. — Completed